Altaire Recalls Up & Up Lubricating Eye Drops for Sterility Concerns
Altaire Pharmaceuticals is recalling Up & Up Intensive Relief Lubricating Eye Drops due to a lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility in an ophthalmic product, which poses a significant risk of serious injury or infection, meeting the criteria for a Severe rating.
Plain-English summary
Altaire Pharmaceuticals, Inc. is recalling specific lots of TRP/ TARGET up & up intensive relief lubricating eye drop, 10 mL. The recall was initiated because of a lack of assurance of sterility in the product.
The affected product is distributed nationwide in the United States. The recall covers specific lot codes 17290 9/19 and 18052 2/20.
Consumers should stop using the recalled eye drops and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- TRP/ TARGET up & up intensive relief lubricating eye drop, 10 mL
- Manufacturer
- Altaire Pharmaceuticals, Inc.
- Category
- Drug — Ophthalmic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 17290 9/19 18052 2/20
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 134 recalled by Altaire Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 134 products in this recall →Related recalls
Same manufacturer · Altaire Pharmaceuticals, Inc.
See all →- SevereCVS Health Dry Eye Relief Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2019-11-27
- SevereCVS Health Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2019-11-27
- SevereCVS Health Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2019-11-27
- SevereAltaire Recalls Equate Support Advanced Twin Pack Due to Sterility Concerns
FDA (Drugs) · 2019-11-27
- SevereAltaire Recalls OCuSOFT Ophthalmic Ointment Due to Sterility Concerns
FDA (Drugs) · 2019-11-27
Same hazard · sterility
See all →- SevereAurolab Trust Recalls FOCUS PI Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2026-10-07
- SevereSterling Recalls Carboxymethylcellulose Sodium Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereSterling Pharmaceutical Recalls Lubricating Tears Due to Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereWalgreens Lubricant Eye Drops Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2026-09-30
- SevereSodium Chloride Ophthalmic Solution Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
Similar recalls
- HighTRP Natural Eyes Allergy Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2024-03-20
- HighTRP Natural Eyes eye drops recalled due to lack of sterility assurance
FDA (Drugs) · 2024-03-20
- HighEye Drops Recall: TRP Eye Twitching Relief Lacks Sterility Assurance
FDA (Drugs) · 2024-03-20
- HighTRP Eye Strain Relief Eye Drops Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2024-03-20
- HighFDA Recalls TRP Natural Eyes Eye Drops Due to Sterility Assurance Issue
FDA (Drugs) · 2023-09-27
- HighTRP Natural Eyes Dryness Relief Eye Drops Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2024-03-20